Last reviewed · How we verify
ROTAVAC 5C -F2
ROTAVAC 5C -F2 is a vaccine that protects against rotavirus infection.
ROTAVAC 5C -F2 is a vaccine that protects against rotavirus infection. Used for Prevention of severe rotavirus gastroenteritis in infants and young children.
At a glance
| Generic name | ROTAVAC 5C -F2 |
|---|---|
| Sponsor | Bharat Biotech International Limited |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
ROTAVAC 5C -F2 contains a weakened form of the rotavirus, which triggers an immune response to provide long-lasting protection against severe rotavirus gastroenteritis in infants and young children.
Approved indications
- Prevention of severe rotavirus gastroenteritis in infants and young children
Common side effects
- Injection site pain
- Fever
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ROTAVAC 5C -F2 CI brief — competitive landscape report
- ROTAVAC 5C -F2 updates RSS · CI watch RSS
- Bharat Biotech International Limited portfolio CI